









市场行情
/
股票
/
nasdaq-gpcr
/

Structure Therapeutics Inc

GPCR

64.940USD

+2.490+3.99%

收盘 12/19, 16:00（美东）报价延迟15分钟

3.94B总市值

亏损市盈率 TTM



Structure Therapeutics Inc

64.940

+2.490+3.99%

概览公司财务分析

概览

公司

财务

分析

关于 Structure Therapeutics Inc 公司

Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. It is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. It is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.

Structure Therapeutics Inc简介



公司代码GPCR

公司名称Structure Therapeutics Inc

上市日期Feb 03, 2023

CEOStevens (Raymond)

员工数量163

证券类型Depository Receipt

年结日Feb 03

公司地址601 Gateway Blvd Suite 900

城市SOUTH SAN FRANCISCO

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编94080

电话16504571978

网址https://structuretx.com/

公司代码GPCR

上市日期Feb 03, 2023

CEOStevens (Raymond)

Structure Therapeutics Inc公司高管



名称

名称/职务

职务

持股

持股变动

Dr. Xichen Lin, Ph.D.

Chief Scientific Officer

49.23K

+885.53%

Mr. Daniel G. Welch

Independent Chairman of the Board

41.17K

Ms. Yingli Ma

Chief Technology Officer

27.34K

+271.74%

Mr. Angus C. Russell

Independent Director

Ms. Sharon Tetlow

Independent Director

Mr. Jun Yoon

Chief Financial Officer, Co-Founder

Dr. Joanne Waldstreicher, M.D.

Independent Director

Mr. Eric L. Dobmeier, J.D.

Independent Director

Dr. Blai Coll, M.D., Ph.D.

Chief Medical Officer

Dr. Raymond Stevens, Ph.D.

Chief Executive Officer, Co-Founder, Director

名称

名称/职务

职务

持股

持股变动

Dr. Xichen Lin, Ph.D.

Chief Scientific Officer

49.23K

+885.53%

Mr. Daniel G. Welch

Independent Chairman of the Board

41.17K

Ms. Yingli Ma

Chief Technology Officer

27.34K

+271.74%

Mr. Angus C. Russell

Independent Director

Ms. Sharon Tetlow

Independent Director

Mr. Jun Yoon

Chief Financial Officer, Co-Founder

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月16日周日

持股股东

股东类型

持股股东

占比

Wellington Management Company, LLP

9.95%

Avoro Capital Advisors LLC

7.46%

Janus Henderson Investors

6.43%

Fidelity Management & Research Company LLC

6.20%

Deep Track Capital LP

6.10%

其他

63.86%

持股股东

占比

Wellington Management Company, LLP

9.95%

Avoro Capital Advisors LLC

7.46%

Janus Henderson Investors

6.43%

Fidelity Management & Research Company LLC

6.20%

Deep Track Capital LP

6.10%

其他

63.86%

股东类型

持股股东

占比

Investment Advisor/Hedge Fund

31.99%

Hedge Fund

25.69%

Investment Advisor

20.19%

Venture Capital

4.37%

Individual Investor

2.51%

Research Firm

1.66%

Private Equity

1.65%

Bank and Trust

0.23%

Pension Fund

0.03%

其他

11.68%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

395

54.88M

90.49%

-15.39M

2025Q2

379

59.75M

103.74%

-16.58M

2025Q1

381

62.21M

108.14%

-12.86M

2024Q4

357

66.09M

115.26%

-5.81M

2024Q3

330

65.93M

115.14%

-2.45M

2024Q2

298

63.40M

110.86%

+11.42M

2024Q1

239

45.01M

96.54%

-1.29M

2023Q4

210

43.42M

93.57%

+9.41M

2023Q3

125

33.38M

93.24%

+15.44M

2023Q2

17.69M

49.41%

+2.82M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Wellington Management Company, LLP

6.88M

11.94%

-915.41K

-11.75%

Jun 30, 2025

Janus Henderson Investors

4.57M

7.94%

+217.81K

+5.00%

Jun 30, 2025

Fidelity Management & Research Company LLC

4.73M

8.21%

-1.07M

-18.47%

Jun 30, 2025

Deep Track Capital LP

5.13M

8.91%

+1.03M

+25.22%

Jun 30, 2025

BVF Partners L.P.

1.66M

2.89%

-109.30K

-6.17%

Aug 11, 2025

Baker Bros. Advisors LP

2.51M

4.36%

+2.15M

+593.86%

Jun 30, 2025

Casdin Capital, LLC

1.23M

2.13%

+525.00K

+75.00%

Jun 30, 2025

RA Capital Management, LP

1.52M

2.63%

Jun 30, 2025

Millennium Management LLC

1.22M

2.12%

+429.90K

+54.41%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

Roundhill GLP-1 & Weight Loss ETF

5.49%

TrueShares Technology, AI & Deep Learning ETF

3.59%

WisdomTree BioRevolution Fund

1.7%

Virtus LifeSci Biotech Clinical Trials ETF

1.02%

ALPS Medical Breakthroughs ETF

0.81%

American Century Focused Dynamic Growth ETF

0.37%

ProShares Ultra Nasdaq Biotechnology

0.26%

Invesco Nasdaq Biotechnology ETF

0.2%

SPDR S&P Emerging Markets Small Cap ETF

0.18%

Fidelity Fundamental Small-Mid Cap ETF

0.18%

Roundhill GLP-1 & Weight Loss ETF

占比5.49%

TrueShares Technology, AI & Deep Learning ETF

占比3.59%

WisdomTree BioRevolution Fund

占比1.7%

Virtus LifeSci Biotech Clinical Trials ETF

占比1.02%

ALPS Medical Breakthroughs ETF

占比0.81%

American Century Focused Dynamic Growth ETF

占比0.37%

ProShares Ultra Nasdaq Biotechnology

占比0.26%

Invesco Nasdaq Biotechnology ETF

占比0.2%

SPDR S&P Emerging Markets Small Cap ETF

占比0.18%

Fidelity Fundamental Small-Mid Cap ETF

占比0.18%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

Structure Therapeutics Inc的前五大股东是谁？



Structure Therapeutics Inc 的前五大股东如下：
Wellington Management Company, LLP持有股份：6.88M，占总股份比例：11.94%。
Janus Henderson Investors持有股份：4.57M，占总股份比例：7.94%。
Fidelity Management & Research Company LLC持有股份：4.73M，占总股份比例：8.21%。
Deep Track Capital LP持有股份：5.13M，占总股份比例：8.91%。
BVF Partners L.P.持有股份：1.66M，占总股份比例：2.89%。